TrialAnnals of oncology : official journal of the European Society for Medical Oncology2016

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

E Ben-Ami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.